Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital

Morais, Beatriz Guzmán; Álvarez, Flor Ángel Ordóñez; Rodríguez, Fernando Santos; Ramos, Silvia Martín; Novo, Gema Fernández

doi:10.1016/j.anpede.2020.12.019

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taşdemir et al [20] performed a retrospective study analyzing 21 patients with SSNS and 22 Published by Francis Academic Press, UK -108-patients with SRNS, 11 patients with SSNS relapsed after initial RTX treatment; among patients with SRNS, 41% were in complete remission at year 1 follow-up and 36% at year 2 follow-up; at year 2 follow-up, 8 patients with SSNS and 4 patients with SRNS did not The SSNS group had a significantly lower number of relapses and longer relapse-free survival, significantly improved serum albumin levels, increased albumin and remission rates in the SRNS group, and reduced use of immunosuppressive drugs. Studies [21] have shown that RTX treatment can reduce the use of immunosuppressive drugs, with a 96.5% reduction in steroid use in the last 3 months of follow-up after RTX treatment with steroids only. It has also been shown [14] that RTX can also improve the quality of life of the children.…”

Section: Rituximab For Rnsmentioning

confidence: 99%

Advances in the treatment of refractory nephrotic syndrome in children

2023

FMSR

View full text Add to dashboard Cite

Nephrotic syndrome is the most common glomerular disease in children, mostly seen in children aged 3-5 years, and is often treated clinically with hormone therapy, but some children with hormone therapy have poor results, manifesting as frequent relapses, hormone dependence or hormone-resistant refractory nephrotic syndrome, and children with long-term hormone use show adverse effects such as growth inhibition, fat metabolism disorders, and infections, which seriously affect the quality of survival. In recent years, various types of immunosuppressants have been used in children with refractory nephrotic syndrome to maintain disease remission, reduce relapses, and reduce the adverse effects of hormones, providing more therapeutic options for treatment.

show abstract

Section: Rituximab For Rnsmentioning

confidence: 99%

Advances in the treatment of refractory nephrotic syndrome in children

2023

FMSR

View full text Add to dashboard Cite

show abstract

Rituximab use in the treatment of children with nephrotic syndrome

Вакуленко¹,

Lytvynova

Posmitjuha

2022

KIDNEYS

View full text Add to dashboard Cite

Background. High recurrence rates of nephrotic syndrome in children and consequences in the form of steroid dependence and a high risk of side effects from corticosteroids as a result involve immunosuppressive steroid-preserving agents that would increase long-term remission. Rituximab, a chimeric anti-CD20 monoclonal antibody that inhibits CD20-mediated B-cell proliferation and differentiation, has been identified as a possible alternative treatment. The purpose of the study — to estimate the efficacy and safety of treatment recurrence of nephrotic syndrome in children using rituximab like we did it on three clinical cases. Materials and methods. The experience of rituximab in children was analyzed according to the databases of Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health and our own study of the treatment of three children with steroid-sensitive nephrotic syndrome was presented. Results. Treatment of nephrotic syndrome in three children who are 5 to 7 years with rituximab was conducted. One child had a second recurrence, two children had a first recurrence. The previous episode of nephrotic syndrome in all children was treated according to the recommendations of KDIGO 2021. All patients received rituximab (two intravenous injections two weeks apart) at a dose of 15 mg/kg for 5–6 hours with prior administration of methylprednisolone at a dose of 7–10 mg/kg. One child had side effects to the first administration of rituximab in the form of hypotension 70/40 and tachycardia 116–118. Reducing the speed of administration helped to eliminate side effects. The next injection in two weeks the child endured well. The other two children had no side effects to both rituximab injections. Moreover after 1 month of rituximab administration was without side effects or hematological changes. The next administration of rituximab is scheduled in 6 months after the last administration with prior control of CD20 level. Conclusions. In general a review of studies of rituximab confirms the high efficacy of the medication in nephrotic syndrome in children and the requirement for long-term evaluation. Rituximab can be considered as a first-line treatment for recurrence of nephrotic syndrome, including in resource-limited settings. Our own experience with rituximab in recurrent nephrotic syndrome has revealed slight short-term side effects.

show abstract

Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital

Cited by 2 publications

References 29 publications

Advances in the treatment of refractory nephrotic syndrome in children

Advances in the treatment of refractory nephrotic syndrome in children

Rituximab use in the treatment of children with nephrotic syndrome

Contact Info

Product

Resources

About